NEW YORK (GenomeWeb News) – Combimatrix said today that the New York State Department of Health has given the Irvine, Calif.-based company a clinical laboratory permit to receive specimens for its DNA Array postnatal test from New Yorkers.
The DNA Array tests, offered through Combimatrix's subsidiary Combimatrix Diagnostics, provide a genomic evaluation on newborns for a range of disorders, including autism, mental retardation, and other birth defects. The tests are based on the firm's arrayCGH technology.
The firm said that it now has received clinical lab licenses from all "major states including California, Florida, Pennsylvania, Maryland, and Rhode Island. It also has accreditation from the Centers for Medicare and Medicaid Services' Clinical Laboratory Improvement Amendments program, and from the College of American Pathologists.